Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024
Altimmune (Nasdaq: ALT) announced it will release its third quarter 2024 financial results on Tuesday, November 12, 2024. The clinical-stage biopharmaceutical company will host a conference call at 8:30 am E.T. on the same day to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website, with a replay available for up to three months after the call.
Altimmune (Nasdaq: ALT) ha annunciato che presenterà i suoi risultati finanziari del terzo trimestre 2024 martedì 12 novembre 2024. La società biofarmaceutica in fase clinica ospiterà una conferenza telefonica alle 8:30 ora orientale dello stesso giorno per discutere i risultati finanziari e fornire aggiornamenti sul business. La conferenza sarà trasmessa in diretta sul sito web delle Relazioni con gli Investitori di Altimmune, con una registrazione disponibile per un massimo di tre mesi dopo la chiamata.
Altimmune (Nasdaq: ALT) anunció que publicará sus resultados financieros del tercer trimestre de 2024 el martes 12 de noviembre de 2024. La empresa biofarmacéutica en etapa clínica llevará a cabo una conferencia telefónica a las 8:30 a.m. E.T. el mismo día para discutir los resultados financieros y proporcionar una actualización del negocio. La conferencia se transmitirá en vivo en el sitio web de Relaciones con Inversores de Altimmune, con una repetición disponible por hasta tres meses después de la llamada.
Altimmune (Nasdaq: ALT)는 2024년 11월 12일 화요일에 2024년 3분기 재무 결과를 발표할 것이라고 발표했습니다. 임상 단계의 생물 제약 회사는 같은 날 오전 8시 30분 동부 표준시(E.T.)에 재무 결과를 논의하고 비즈니스 업데이트를 제공하기 위해 컨퍼런스 콜을 개최합니다. 이 컨퍼런스 콜은 Altimmune의 투자자 관계 웹사이트에서 생중계되며, 통화 후 최대 3개월 동안 재생할 수 있습니다.
Altimmune (Nasdaq: ALT) a annoncé qu'il publiera ses résultats financiers du troisième trimestre 2024 le mardi 12 novembre 2024. La société biopharmaceutique en phase clinique organisera une conférence téléphonique à 8h30 H.E. le même jour pour discuter des résultats financiers et fournir une mise à jour sur ses activités. La conférence téléphonique sera diffusée en direct sur le site web des Relations Investisseurs d'Altimmune, avec une rediffusion disponible jusqu'à trois mois après l'appel.
Altimmune (Nasdaq: ALT) gab bekannt, dass am Dienstag, dem 12. November 2024, die Finanzergebnisse für das dritte Quartal 2024 veröffentlicht werden. Das biopharmazeutische Unternehmen in der klinischen Phase wird am selben Tag um 8:30 Uhr E.T. eine Telefonkonferenz veranstalten, um die Finanzergebnisse zu besprechen und ein Update zum Geschäft zu geben. Die Telefonkonferenz wird live auf der Investor Relations-Website von Altimmune übertragen, mit einer Wiederholung, die bis zu drei Monate nach dem Anruf verfügbar ist.
- None.
- None.
GAITHERSBURG, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2024 financial results on Tuesday, November 12, 2024 and will provide a business update.
Altimmune management will host a conference call at 8:30 am E.T. on November 12 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors.
Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Company Contact:
Vipin Garg
President and Chief Executive Officer
Phone: 240-654-1450
ir@altimmune.com
Investor Contacts:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Julia Weilman
Burns McClellan
Phone: 646-732-4443
jweilman@burnsmc.com
Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com
This press release was published by a CLEAR® Verified individual.
FAQ
When will Altimmune (ALT) report Q3 2024 earnings?
What time is Altimmune's (ALT) Q3 2024 earnings call?
Where can I listen to Altimmune's (ALT) Q3 2024 earnings call?
